Brain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression.
Journal
Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
20
03
2019
revised:
26
06
2019
accepted:
02
07
2019
pubmed:
7
7
2019
medline:
28
4
2021
entrez:
7
7
2019
Statut:
ppublish
Résumé
The results of several meta-analyses suggest that eicosapentaenoic acid (EPA) supplementation is therapeutic in managing the symptoms of major depression. It was previously assumed that because EPA is extremely low in the brain it did not cross the blood-brain barrier and any therapeutic effects it exerted would be via the periphery. However, more recent studies have established that EPA does enter the brain, but is rapidly metabolised following entry. While EPA does not accumulate within the brain, it is present in microglia and homeostatic mechanisms may regulate its esterification to phospholipids that serve important roles in cell signaling. Furthermore, a variety of signaling molecules from EPA have been described in the periphery and they have the potential to exert effects within the brain. If EPA is confirmed to be therapeutic in major depression as a result of adequately powered randomized clinical trials, future research on brain EPA metabolism could lead to the discovery of novel targets for treating or preventing major depression.
Identifiants
pubmed: 31278982
pii: S0889-1591(19)30302-2
doi: 10.1016/j.bbi.2019.07.001
pii:
doi:
Substances chimiques
Phospholipids
0
Docosahexaenoic Acids
25167-62-8
Eicosapentaenoic Acid
AAN7QOV9EA
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-28Subventions
Organisme : NCCIH NIH HHS
ID : R01 AT008375
Pays : United States
Informations de copyright
Copyright © 2019. Published by Elsevier Inc.